Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.
Discovering & validating novel therapeutic targets to add to the immuno-oncology arsenal requires refined preclinical models that meet needs for suitability, scalability & clinical relevancy throughout the phases of target discovery & drug validation.
By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen
Past decades have witnessed significant efforts toward the development of 3D cell cultures. They are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.
Cobra Biologics, has announced it is to expand operations at its sites in UK and Sweden to meet the increased demand of gene and immunotherapy companies to fast track their portfolios through to in-market supply.
Plasticell has announced it has secured Biomedical Catalyst funding of over £920,000 from Innovate UK to create a safe, effective red blood cell substitute for human clinical transfusion, in collaboration with stem cell scientists at the University of Edinburgh.
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays & leading provider of peptide synthesizers and reagents, have announced it has introduced a new kit for early-stage biotherapeutic pharmacokinetic (PK) studies.